par Tate, Sarah K;Singh, Rinki;Hung, Chin-Chuan;Tai, John Jen;Depondt, Chantal ;Cavalleri, Gianpiero L;Sisodiya, Sanjay M;Goldstein, David B;Liou, Horng-Huei
Référence Pharmacogenetics and genomics, 16, 10, page (721-726)
Publication Publié, 2006-10
Référence Pharmacogenetics and genomics, 16, 10, page (721-726)
Publication Publié, 2006-10
Article révisé par les pairs
Résumé : | A broad range of phenytoin doses is used in clinical practice, with the final 'maintenance' dose normally determined by trial and error. A common functional polymorphism in the SCN1A gene (one of the genes encoding the drug target) has been previously associated with maximum dose of phenytoin used clinically, and also maximum dose of carbamazepine, another antiepileptic drug with the same drug target. |